{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:06:56Z","timestamp":1769742416176,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ajoc.2023.101925","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T11:56:46Z","timestamp":1694087806000},"page":"101925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-4179","authenticated-orcid":false,"given":"Sara L.","family":"Weidmayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ajoc.2023.101925_bib1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2023.101925_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101925_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101925_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101925_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ajoc.2023.101925_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/ICU.0b013e328358b94a","article-title":"Ocular myasthenia gravis","volume":"23","author":"Vaphiades","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajoc.2023.101925_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"1","author":"Walker","year":"1934","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajoc.2023.101925_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101925_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.ajoc.2023.101925_bib10","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ajoc.2023.101925_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577767","article-title":"Eculizumab treatment for myasthenia gravis subgroups: 2021 update","volume":"362","author":"Jiao","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ajoc.2023.101925_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.ajoc.2023.101925_bib13","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ajoc.2023.101925_bib14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101925_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101925_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular myasthenia","volume":"36","author":"Al-Haidar","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.ajoc.2023.101925_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ajoc.2023.101925_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mus.26512","article-title":"Eculizumab: a complementary addition to existing long-term therapies for myasthenia gravis","volume":"60","author":"Edmundson","year":"2019","journal-title":"Muscle Nerve"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993623001330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993623001330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:04:28Z","timestamp":1762527868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993623001330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":18,"alternative-id":["S2451993623001330"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101925","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101925"}}